X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator

MT Newswires Live

2025/01/24

X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.

The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.

The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2505409866"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505409866\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505409866?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-24 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505409866","market":"fut","top_or_hot":-1,"title":"X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator","media":"MT Newswires Live","content":"<html><body><p> X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.</p><p>The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.</p><p>The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 Pharmaceuticals Says Marketing Application for Mavorixafor Validated for Review by EU Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-24 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.</p><p>The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.</p><p>The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XFOR","symbol_name":"X4制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505409866","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505409866","pubTimestamp":1737729843,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"X4 Pharmaceuticals  said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XFOR":"X4制药","BK4139":"生物科技","BK4156":"煤与消费用燃料"},"translate_title":"X4 Pharmaceuticals表示Mavorixafor的营销申请已通过欧盟监管机构审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}